DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection

Journal of Immunology

Volumn 162, Issue 8, 1999, Pages 4790-4795

  Syrengelas, Athanasia D ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; DNA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HELPER CELL; HUMORAL IMMUNITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR IMMUNITY;

EID: 0033561635     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Stevenson, F. K., D. Zhu, C. A. King, L. J. Ashworth, S. Kumar, and R. E. Hawkins. 1995. Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145:211.
2. Syrengelas, A., T. T. Chen, and R. Levy. 1996. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med. 2:1038.
3. Hakim, I., S. Levy, and R. Levy. 1996. A nine-ammo acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J. Immunol. 157:5503.
4. King, C. A., M. B. Spellerberg, D. Zhu, J. Rice, S. S. Sahota, A. R. Thompsett, T. J. Hamblin, J. Radl, and F. K. Stevenson. 1998. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med 4:1281.
5. Bergman, Y., and J. Haimovich. 1977. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur. J. Immunol. 7:413.
6. 2 fragments against idiotypic determinants of its cell surface IgM. J. Immunol. 131:1600.
7. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145:1029.
8. Kwak, L. W., H. A. Young, R. W. Pennington, and S. D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T cell response. Proc. Natl. Acad. Sci. USA 93:10972.
9. Kwak, L. W., R. Pennington, L. Boni, A. C. Ochoa, R. J. Robb, and M. C. Popescu. 1998. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol. 160:3637.
10. George, A J., A. L. Tutt, and F. K. Stevenson. 1987. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCLI. J. Immunol. 138:628.
11. McDonnell, W. M., and F. K. Askari. 1996. Molecular medicine DNA vaccines N. Engl. J. Med. 334:42.
12. Hawkins, R. E., D. Zhu, M. Ovecka, G. Winter, T. J. Hamblin, A. Long, and F. K. Stevenson. 1994. Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83:3279.
13. Starnes, C. O., W. L. Carroll, M. J. Campbell, L. L. Houston, G. Apell, and R. Levy. 1988. Heterogeneity of a murine B cell lymphoma: isolation and characterization of idiotypic variants. J. Immunol. 141:333.
14. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435.
15. Tao, M. H., and R. Levy. 1993. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755.
16. Slavin, S., and S. Strober. 1978. Spontaneous murine B-cell leukemia. Nature 272:624.
17. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
18. Maloney, D. G., M. S. Kaminski, D. Burowski, J. Haimovich, and R. Levy. 1985. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191.
19. Kaminski, M. S., K. Kitamura, D. G. Maloney, M. J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma: a study of hybridoma class switch variants. J. Immunol. 136:1123.
20. Liu, S. J., Y. P. Sher, C. C. Ting, K. W. Liao, C. P. Yu, and M. H. Tao. 1998. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 92:2103.
21. Funakoshi, S., D. L. Longo, M. Beckwith, D. K. Conley, G. Tsarfaty, I. Tsarfaty, R. J. Armitage, W. C. Fanslow, M. K. Spriggs, and W. J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83:2787.
22. Vuist, W. M., R. Levy, and D. G. Maloney. 1994. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899.
23. Funakoshi, S., D. L. Longo, and W. J. Murphy. 1996. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal anti-bodies against human B-cell lymphomas. J. Immunother. 19:93.
24. Ghetie, M. A., L. J. Picker, J. A. Richardson, K. Tucker, J. W. Uhr, and E. S. Vitetta. 1994. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells SCID mice by inducing cell cycle arrest Blood 83:1329.
25. Tutt, A. L., R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. Parkhouse, G. G. Klaus, and M. J. Glennie. 1998. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161:3176.
26. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:2369.
27. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122.
28. Irvine, K. R., J. B. Rao, S. A. Rosenberg, and N. P. Restifo. 1996. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156:238.
29. Schirmbeck, R., W. Bohm, and J. Reimann. 1996. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J. Immunol. 157:3550.
30. Ross, H. M., L. W. Weber, S. Wang, G. Piskun, R. Dyall, P. Song, Y. Takechi, J. Nikolic-Zugic, A. N. Houghton, and J. J. Lewis. 1997. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization Clin. Cancer Res. 3:2191.
31. Schreurs, M. W. J., A. J. de Boer, C. G. Figdor, and G. J. Adema. 1998. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 58:2509.
32. Cao, W., B. A. Myers-Powell, and T. J. Braciale. 1994. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J. Exp. Med. 179:195.
33. Chakrabarti, D., and S. K. Ghosh. 1992. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. I. Role of idiotypic immunoglobulin. Cell. Immunol. 142:54.
34. Lynch, R. G., R. J. Graff, S. Sirisinha, E. S. Simms, and H. N. Eisen. 1972. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69:1540.
35. Frikke, M. J., S. H. Bridges, and R. G. Lynch. 1977. Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity. J. Immunol. 118:2206.
36. Daley, M. J., H. M. Gebel, and R. G. Lynch. 1978. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J. Immunol. 120:1620.
37. + T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur. J. Immunol. 25:3079.
38. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 89:3129.
39. Campbell, M. J., W. Carroll, S. Kon, K. Thielemans, J. B. Rothbard, S. Levy, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139:2825.
40. Kaminski, M. S., K. Kitamura, D. G. Maloney, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein. J. Immunol. 138:1289.
41. George, A. J., S. G. Folkard, T. J. Hamblin, and F. K. Stevenson. 1988. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 141:2168.
42. Spellerberg, M. B., D. Zhu, A. Thompsett, C. A. King, T. J. Hamblin, and F. K. Stevenson. 1997. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to letanus toxin fragment Cl. J. Immunol. 159:1885.